Medicus Pharma (NASDAQ:MDCX) announced that it will present new Phase 1 clinical data on its long-acting gonadotropin-releasing hormone (GnRH) antagonist Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting in April 2026.
The company said its abstract, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers,” has been accepted for e-Poster presentation at the meeting, which will be held April 22 to 24 in Las Vegas.
According to Medicus, the data are derived from two randomized, placebo-controlled Phase 1 studies involving a total of 48 healthy premenopausal women. Participants received a single subcutaneous injection of Teverelix at doses of 30 mg, 45 mg, or 60 mg, or placebo, and were monitored for approximately one month. The studies evaluated pharmacokinetics, hormone suppression, bone turnover markers, and safety.
The company reported that Teverelix led to rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) within 24 hours of dosing.
Estradiol levels declined in a dose-dependent and reversible manner, with some participants reaching levels within the clinically referenced Barbieri window of 30–50 pg/mL. At higher doses, hormone suppression was sustained for up to two to three weeks following a single injection.
Medicus said bone turnover markers remained stable during the study period, indicating no evidence of short-term bone loss.
The company also reported a favorable safety profile, with no drug-related serious adverse events and only mild-to-moderate treatment-emergent adverse events observed.
Teverelix is formulated as a long-acting injectable microcrystalline suspension and is designed to immediately block GnRH receptors. Medicus noted that, unlike GnRH agonists, the drug does not cause an initial hormonal surge.
The company added that this mechanism may be relevant in patient populations where cardiovascular risk is a concern, although it highlighted that further clinical validation is required.
“We believe that these findings reinforce the versatility of Teverelix as a long-acting GnRH antagonist platform,” Medicus CEO Dr Raza Bokhari said in a statement.
“In addition to its development in prostate cancer and acute urinary retention relapse prevention, we believe these Phase 1 results support advancement into women’s health indication, endometriosis, a condition affecting ~10% of women of reproductive age worldwide, where controlled, reversible hormone suppression and bone safety are critical.”
Beyond Teverelix, Medicus said it is advancing other programs under a strategy focused on progressing assets through Phase 2 proof-of-concept before seeking licensing or strategic partnerships.
The company also provided an update on SkinJect, its dissolvable microneedle array platform delivering doxorubicin for the treatment of basal cell carcinoma.
Medicus said that Phase 2 enrollment for the SkinJect study has been completed with 90 patients across nine US sites, with topline data expected in the first quarter of 2026. An end-of-Phase 2 meeting with the US Food and Drug Administration is planned for the first half of the year.